» Articles » PMID: 34040936

Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines

Overview
Journal Glob Heart
Publisher Ubiquity Press
Date 2021 May 27
PMID 34040936
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Key Highlights: Pulmonary arterial hypertension (PAH) is a rare progressive subtype of pulmonary hypertension with poor overall prognosis and outcomes.Prompt and accurate diagnosis of PAH remains an unmet challenge in low- and middle-income countries due to poor knowledge about the etiology and pathophysiology of this syndrome. Also, the symptoms and signs of early-stage PAH are usually nonspecific or undetectable in newborn and infants, thus presenting a challenge for physicians to establish early diagnoses of PAH.The challenging factors in low- and middle-income countries, especially Indonesia archipelago are limitations of healthcare infrastructure, limited expertise, lack of awareness, lack of timely PAH screening strategies, poor antenatal care and unpredictable availability of PAH medications.There are no specific national guidelines focusing on diagnostic workup and treatment of PAH in Indonesia. Under-utilization of treatment guidelines and lack of adequate diagnostic treatment facilities have resulted in sub-optimal management of PAH patients in Indonesia.Adherence to international guidelines is an important aspect of PAH management in Indonesia. Updated disease and functional classifications of PAH as per international guidelines along with new research findings on prognostic factors can help in making better management decisions for PAH patients at different stages of the disease.

Citing Articles

An insight into Indonesia's progress for newborn screening program: What is currently going on.

Octavius G, Daleni V, Sagala Y Heliyon. 2024; 10(13):e33479.

PMID: 39035496 PMC: 11259875. DOI: 10.1016/j.heliyon.2024.e33479.


Increased serum activin A level in congenital heart disease-associated pulmonary artery hypertension: A comparative study from the COHARD-PH registry.

Hadwiono M, Hartopo A, Wasityastuti W, Anggrahini D, Ryanto G, Emoto N Pulm Circ. 2023; 13(3):e12280.

PMID: 37609359 PMC: 10440839. DOI: 10.1002/pul2.12280.


An Insight into Indonesia's Challenges in Implementing Newborn Screening Programs and Their Future Implications.

Octavius G, Daleni V, Sagala Y Children (Basel). 2023; 10(7).

PMID: 37508713 PMC: 10378005. DOI: 10.3390/children10071216.


Prognostic Value for Mortality of Plasma Bioactive Adrenomedullin in Patients with Pulmonary Arterial Hypertension: A Sub Analysis of the Biomarker Study in the COHARD-PH Registry.

Hartopo A, Anggrahini D, Dinarti L, Schafer A, Bergmann A, Fachiroh J Medicina (Kaunas). 2023; 59(4).

PMID: 37109706 PMC: 10140828. DOI: 10.3390/medicina59040748.

References
1.
Baldi F, Fuso L, Arrighi E, Valente S . Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag. 2014; 10:825-39. PMC: 4199557. DOI: 10.2147/TCRM.S48920. View

2.
Dhariwal A, Bavdekar S . Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med. 2015; 61(3):181-92. PMC: 4943407. DOI: 10.4103/0022-3859.159421. View

3.
Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M . Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur Respir Rev. 2019; 28(154). PMC: 9488628. DOI: 10.1183/16000617.0050-2019. View

4.
Dinarti L, Hartopo A, Kusuma A, Satwiko M, Hadwiono M, Pradana A . The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord. 2020; 20(1):163. PMC: 7137468. DOI: 10.1186/s12872-020-01434-z. View

5.
Wang T, Chen L, Yang T, Huang P, Wang L, Zhao L . Congenital Heart Disease and Risk of Cardiovascular Disease: A Meta-Analysis of Cohort Studies. J Am Heart Assoc. 2019; 8(10):e012030. PMC: 6585327. DOI: 10.1161/JAHA.119.012030. View